Posted inHealthcare Highlight News
Takeda’s Dengue Vaccine shows Effect in Children ages 4-16 Years
New England Journal of Medicine publishes primary endpoint analysis from the ongoing Phase 3 study of Takeda’s dengue vaccine candidate. Takeda Pharmaceutical Company Limited (“Takeda”) announced the results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue…